Wells Fargo lowered the firm’s price target on Avrobio to $2.00 from $2.50 and keeps an Overweight rating on the shares. There is upside to current levels based on cash position alone with Avrobio exploring strategic alternatives, and Wells Fargo sees further upside from the company’s technology and manufacturing platforms, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AVRO:
- Avrobio downgraded to Neutral at Wedbush after wind down announcement
- Avrobio downgraded to Neutral from Outperform at Wedbush
- Avrobio to conduct exploration of strategic alternatives
- Biotech Alert: Searches spiking for these stocks today
- Avrobio Soars on Offloading Gene Therapy to Novartis for $87.5M